definiens: means, with respect to an Alp ha - Synuclein Antibody, ( a ) the fragments and altern ate formats of such Alpha - Synuclein Antibody such as Fa b, Fab2, scFVs, nanobodies, intrabodies, diabodies, ( b ) mono- or multi - specific and mono- or multi - valent i mmunoglobulin molecules arising from fusions or oth er modifications of or to such Alpha - Synuclein Antibod y, in each of the foregoing cases ( ( a ) and ( b ) ) tha t specifically binds to Alpha - Synuclein and ( c ) any immunoglobulin molecule ( including any fragments and alternative formats thereof, such as Fab, Fab2, scFVs, nanobodies, intr abodies, diabodies, and mono- or multi - specific and mono- or multi - valent immunoglobulin molecules arising from fusions or other modifications of or to such immuno globulin molecule ) that comprises any modification to a CDR of such Alpha - Synuclein Antibody that results in gr eater than eighty percent ( 80 % ) sequence identity relative to the original CDR of such Alpha - Synuclein Antibody p rior to the modification ( such CDR sequence identity determ ined by the Clustal W software program, Version clustalw1.83, January 30, 2003, set to default sett ings, or such other similar software program as may be mutually agreed upon by the Parties ) and binds to Alpha - Synu clein, as evidenced for purposes of this clause ( c ) by the ability of such immunoglobulin molecule to inhibit binding of the original unmodified Alpha - Synuclein Antibody to Alpha - Synuclein by at least seventy percent ( 70 % ) in assays conducted in each of the following orie ntations : ( x ) unmodified Alpha - Synuclein Antibody immobilized and such immunoglobulin molecule is in solution an d ( y ) such immunoglobulin molecule is immobilized and the unmodified Alpha - Synuclein Antibody is in solution